AREG and neoplasm: We found that TGFB1/EGFR, LTA/LTBR, CD46/JAG1, and AREG/EGFR ligand‐receptor pairs were stronger in CD4+ T cell‐Plac1+ tumor cells than in CD4+ T cell‐Plac1− tumor cells, among which LTA/LTBR expression was highly specific for Tregs and Plac1+ cells (Figures7A, S14A,B, Supporting Information).